D. Stanescu (Brussels, Belgium), C. Kroegel (Jena, Germany)
Combined nebulization therapy in acute asthma exacerbation
S. I. Ovtcharenko, O. A. Peredelskaya, N. V. Tchitchkova, V. I. Makolkin (Moscow, Russia)
|  |
The treatment with flunisolide in severe steroid asthmatics: the three-year follow-up study
E. I. Vanetik, L. N. Tislenko, Y. A. Tereschenko (Krasnoyarsk, Russia)
| |
Dose-dependent effects of salbutamol (S) and fenoterol (F) in patients with bronchial asthma (BA) and ischaemic heart disease (IHD)
B. A. Tcherniak, J. N. Krasnova, A. A. Dzizinsky (Irkutsk, Russia)
| |
Use of budesonide suspension during the exacerbation of severe steroid-dependent bronchial asthma
M. S. Smirnova (Nizhniy Novgorod, Russia)
| |
Combined therapy of severe osteoporosis for patients with bronchial asthma
I. Baranova, B. Shmushkovich, K. Gadjiev, A. Chuchalin (Moscow, Russia)
| |
Use of asthma rescue medication in response to nonsymptom triggers
M. Meguro, P. W. Jones (London, United Kingdom)
| |
Improved asthma control with budesonide/formoterol via a single inhaler, compared with budesonide alone, in moderate persistent asthma
R. Buhl, O. Zetterstrom, H. Mellem, M. Perpina, J. Hedman, S. O'Neill, S. Peterson (Mainz, Germany; Stockholm, Lund, Sweden; Oslo, Norway; Valencia, Spain; Lahti, Finland; Dublin, Ireland)
| |
Budesonide and formoterol in a single inhaler quickly gains asthma control compared with fluticasone propionate in mild asthma
A. Eliraz, C. C. Fritscher, C. M. R. Perez, W. Boonsawat, A. N. Nang, P. Bardin, H. P. Kao (Rehovot, Israel; Porto Alegre, Brazil; Mexico City, Mexico; Khon Kaen, Thailand; Hanoi, Vietnam; Tygerberg, South Africa; Taipei, Taiwan)
| |
Synergistic inhibition of oxidative burst in human eosinophils by combination treatment with formoterol and budesonide
A. Miller-Larsson, S. Persdotter, K. Lexmuller, M. Lindahl, R. Brattsand (Lund, Sweden)
| |
Economic evaluation of salmeterol/fluticasone combination versus budesonide plus formoterol in Spain
J. F. Alonso, C. Badiola, A. Kielhorn (Madrid, Spain; Greenford, United Kingdom)
| |
Formoterol is more potent and more effective than salmeterol in the inhibition of oxidative burst in human eosinophils
A. Miller-Larsson, S. Persdotter, A. Jerre, R. Brattsand (Lund, Sweden)
| |
Comparison of 800 μg once vs. 400 μg twice daily inhaled budesonide in patients with moderate asthma
D. Vervloet, T. Fontaine, L. Bernabeu, P. Gaillot, J. Ostinelli (Marseille, St. Quentin, Chauny, Annonay, Rueil-Malmaison, France)
| |
Cost-effectiveness of fluticasone compared with beclomethasone extra fine aerosol
J. F. O'Reilly, P. S. Stephenson, K. E. Evans (Blackpool, Suffolk, Cheshire, United Kingdom)
| |
Beclomethasone extra fine aerosol more cost-effective then budesonide turbo inhaler
J. F. O'Reilly, P. S. Stephenson, K. E. Evans (Blackpool, Suffolk, Cheshire, United Kingdom)
| |
Low dose inhaled budesonide with and without formoterol in steroid free patients with mild persistent asthma
P. M. O'Byrne, P. J. Barnes, R. Rodriguez-Roisin, E. Runnerström, T. Sandström, K. Svensson, A. Tattersfield (Hamilton, Canada; London, Nottingham, United Kingdom; Barcelona, Spain; Lund, Umeå, Sweden)
| |
New method of treatment of steroid-dependant asthma with inhalations of ultra-low doses of alkylating drug: clinical results
K. A. Zykov, V. I. Shevelev, A. I. Veshkina, L. U. Matko, U. I. Demidov, E. I. Sokolov (Moscow, Russia)
| |
Montelukast causes additive benefit in acute asthma
S. A. Green, C. A. Camargo, Jr, H. A. Smithline, R. Nowak, M. P. Malice, T. F. Reiss (Rahway, Boston, Springfield, Detroit, United States Of America)
| |
Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects
M. Middle, E. Terblanche, V. Perrin, M. Hertog (George, Bloemfontein, South Africa; London, United Kingdom; Leiderdorp, The Netherlands)
| |
Extracorporal therapy of bronchial asthma
A. V. Karaulov, S. I. Sokurenko, A. N. Fedoseev (Moscow, Russia)
| |